A traceable and bone-targeted nanoassembly based on defect-related luminescent mesoporous silica for enhanced osteogenic differentiation

2017 ◽  
Vol 5 (8) ◽  
pp. 1585-1593 ◽  
Author(s):  
Huihui Ren ◽  
Shizhu Chen ◽  
Yanan Jin ◽  
Cuimiao Zhang ◽  
Xinjian Yang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Mesoporous Silica ◽  
Osteogenic Differentiation ◽  
Silica Nanoparticles ◽  
Drug Delivery System ◽  
Delivery System ◽  
Mesoporous Silica Nanoparticles ◽  
Bone Targeting

A traceable drug delivery system based on gadolinium-labeled mesoporous silica nanoparticles was developed for bone targeting and enhanced osteogenic differentiation.

Wetting transition in nanochannels for biomimetic free-blocking on-demand drug transport

2018 ◽  
Vol 6 (39) ◽  
pp. 6269-6277 ◽  
Author(s):  
Yaya Cheng ◽  
Xiangyu Jiao ◽  
Liang Zhao ◽  
Yang Liu ◽  
Fang Wang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Drug Delivery System ◽  
Delivery System ◽  
Drug Transport ◽  
Mesoporous Silica Nanoparticles ◽  
Wetting Transition ◽  
On Demand ◽  
Inner Surface

Inspired by aquaporins in nature, herein, a biomimetic free-blocking on-demand drug delivery system is proposed, which is constructed by controlling the wettability of the inner surface of nanochannels on mesoporous silica nanoparticles (MSNs).

scholarly journals ADAM9-Responsive Mesoporous Silica Nanoparticles for Targeted Drug Delivery in Pancreatic Cancer

Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3321
Author(s):  
Etienne J. Slapak ◽  
Lily Kong ◽  
Mouad el Mandili ◽  
Rienk Nieuwland ◽  
Alexander Kros ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Conditioned Medium ◽  
Drug Delivery System ◽  
Delivery System ◽  
Targeted Drug Delivery ◽  
Mesoporous Silica Nanoparticles ◽  
Pdac Cell ◽  
Targeted Drug

Pancreatic ductal adenocarcinoma (PDAC) has the worst survival rate of all cancers. This poor prognosis results from the lack of efficient systemic treatment regimens, demanding high-dose chemotherapy that causes severe side effects. To overcome dose-dependent toxicities, we explored the efficacy of targeted drug delivery using a protease-dependent drug-release system. To this end, we developed a PDAC-specific drug delivery system based on mesoporous silica nanoparticles (MSN) functionalized with an avidin–biotin gatekeeper system containing a protease linker that is specifically cleaved by tumor cells. Bioinformatic analysis identified ADAM9 as a PDAC-enriched protease, and PDAC cell-derived conditioned medium efficiently cleaved protease linkers containing ADAM9 substrates. Cleavage was PDAC specific as conditioned medium from leukocytes was unable to cleave the ADAM9 substrate. Protease linker-functionalized MSNs were efficiently capped with avidin, and cap removal was confirmed to occur in the presence of PDAC cell-derived ADAM9. Subsequent treatment of PDAC cells in vitro with paclitaxel-loaded MSNs indeed showed high cytotoxicity, whereas no cell death was observed in white blood cell-derived cell lines, confirming efficacy of the nanoparticle-mediated drug delivery system. Taken together, this research introduces a novel ADAM9-responsive, protease-dependent, drug delivery system for PDAC as a promising tool to reduce the cytotoxicity of systemic chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document